This is an extract from the RBS Morgans research giving the milestone planned timeline and their relative thoughts of their effectiveness if achieved.
This information will be available from the TIS web site but just encapsulates it well.
Regards...........
Table 1 : Milestone table Expected date Milestone Expected catalyst Jul-11 Interim results EU multicentre venous ulcer trial ? full results in Sept Positive 3QCY11 (was 2QCY11) Formal FDA request for designation as a device Positive 4QCY11 Regulatory approval for sale: starting for Rest of World Positive 1QCY12 Approval for sale in EU Very Positive 2QCY12 Sales launch in EU Very Positive 3QCY12 Venous ulcer clinical trial completed in US Positive 3QCY12 World-wide launch outside EU and US: starting for Rest of World Positive 2QCY13 Approval VitroGro? for treatment of venous ulcers Very Positive 3QCY13 US launch of VitroGro? for treatment of venous ulcers Very Positive 2QCY13 Diabetic and pressure ulcer clinical trials completed in US Positive 4QCY13 Approval of VitroGro? for treatment of diabetic and pressure
ulcers in US Very Positive 1QCY14 US launch of VitroGro? for treatment of diabetic and pressure ulcers Positive Source: Company data, RBS Morgans forecasts
TIS Price at posting:
60.0¢ Sentiment: Hold Disclosure: Held